|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM258506407 |
| 003 |
DE-627 |
| 005 |
20250219205236.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20160229-07
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0861.xml
|
| 035 |
|
|
|a (DE-627)NLM258506407
|
| 035 |
|
|
|a (NLM)26985798
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Choi, Catherine S
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related Macular Degeneration With OCT Segmentation Volumetric Analysis
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.12.2016
|
| 500 |
|
|
|a Date Revised 13.11.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2016, SLACK Incorporated.
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: To use automated segmentation software to analyze spectral-domain optical coherence tomography (SD-OCT) scans and evaluate the effectiveness of aflibercept (Eylea; Regeneron, Tarrytown, NY) in the treatment of patients with exudative age-related macular degeneration (AMD) refractory to other treatments
|
| 520 |
|
|
|a PATIENTS AND METHODS: Retrospective chart review of 16 patients refractory to bevacizumab (Avastin; Genentech, South San Francisco, CA)/ranibizumab (Lucentis; Genentech, San Francisco, CA) treatment was conducted. Visual acuity, central foveal thickness (CFT), maximum fluid height, pigment epithelial detachment (PED) volume, sub-retinal fluid (SRF) volume, fluid-free time interval, and adverse effects were evaluated. Automated segmentation analysis was used to quantify improvement
|
| 520 |
|
|
|a RESULTS: With aflibercept treatment, there was a statistically significant improvement in visual acuity by 1 line (P = .020), in CFT by 74.02 µm (P = .001), and in maximum fluid height by 31.9 µm (P= .011). Total PED and SRF volume also decreased significantly by 1.50 µm(3) × 10(8) µm(3) (P = .013). Anatomic improvement was confirmed by automated segmentation analysis
|
| 520 |
|
|
|a CONCLUSION: This study demonstrates utility of automated segmentation software in quantifying anatomic improvement with aflibercept treatment in exudative AMD refractory to other anti-vascular endothelial growth factor treatments
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Angiogenesis Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
| 650 |
|
7 |
|a VEGFA protein, human
|2 NLM
|
| 650 |
|
7 |
|a Vascular Endothelial Growth Factor A
|2 NLM
|
| 650 |
|
7 |
|a aflibercept
|2 NLM
|
| 650 |
|
7 |
|a 15C2VL427D
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Vascular Endothelial Growth Factor
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 700 |
1 |
|
|a Zhang, Li
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Abràmoff, Michael D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sonka, Milan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shifera, Amde Selassie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kay, Christine N
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 47(2016), 3 vom: 03. März, Seite 245-51
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnas
|
| 773 |
1 |
8 |
|g volume:47
|g year:2016
|g number:3
|g day:03
|g month:03
|g pages:245-51
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20160229-07
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 912 |
|
|
|a GBV_ILN_1127
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 47
|j 2016
|e 3
|b 03
|c 03
|h 245-51
|